Bausch + Lomb (BLCO) Competitors

$16.23 +0.20 (+1.22%)

Closing price 05/13/2026 03:59 PM Eastern

Extended Trading

$16.00 -0.23 (-1.39%)

As of 05/13/2026 06:04 PM Eastern

BLCO vs. ZBH, SNN, SOLV, PEN, and GKOS

Should you buy Bausch + Lomb stock or one of its competitors? MarketBeat compares Bausch + Lomb with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bausch + Lomb include Zimmer Biomet (ZBH), Smith & Nephew SNATS (SNN), Solventum (SOLV), Penumbra (PEN), and Glaukos (GKOS). These companies are all part of the "medical equipment" industry.

How does Bausch + Lomb compare to Zimmer Biomet?

Bausch + Lomb (NYSE:BLCO) and Zimmer Biomet (NYSE:ZBH) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

Zimmer Biomet has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.13	-$360M	-$0.62	N/A
Zimmer Biomet	$8.23B	1.94	$705.20M	$3.85	21.47

In the previous week, Zimmer Biomet had 7 more articles in the media than Bausch + Lomb. MarketBeat recorded 10 mentions for Zimmer Biomet and 3 mentions for Bausch + Lomb. Bausch + Lomb's average media sentiment score of 1.18 beat Zimmer Biomet's score of 0.85 indicating that Bausch + Lomb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Zimmer Biomet	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

11.1% of Bausch + Lomb shares are owned by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are owned by institutional investors. 1.5% of Bausch + Lomb shares are owned by insiders. Comparatively, 1.3% of Zimmer Biomet shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Bausch + Lomb has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market. Comparatively, Zimmer Biomet has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market.

Bausch + Lomb currently has a consensus target price of $18.08, indicating a potential upside of 11.45%. Zimmer Biomet has a consensus target price of $102.80, indicating a potential upside of 24.35%. Given Zimmer Biomet's stronger consensus rating and higher possible upside, analysts plainly believe Zimmer Biomet is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Zimmer Biomet	3 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.26

Zimmer Biomet has a net margin of 9.05% compared to Bausch + Lomb's net margin of -4.21%. Zimmer Biomet's return on equity of 13.24% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-4.21%	3.60%	1.69%
Zimmer Biomet	9.05%	13.24%	7.28%

Summary

Zimmer Biomet beats Bausch + Lomb on 14 of the 17 factors compared between the two stocks.

How does Bausch + Lomb compare to Smith & Nephew SNATS?

Smith & Nephew SNATS (NYSE:SNN) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Smith & Nephew SNATS has higher revenue and earnings than Bausch + Lomb.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.16B	2.07	$625M	N/A	N/A
Bausch + Lomb	$5.10B	1.13	-$360M	-$0.62	N/A

In the previous week, Bausch + Lomb had 1 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 3 mentions for Bausch + Lomb and 2 mentions for Smith & Nephew SNATS. Bausch + Lomb's average media sentiment score of 1.18 beat Smith & Nephew SNATS's score of 0.23 indicating that Bausch + Lomb is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew SNATS	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bausch + Lomb	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

25.6% of Smith & Nephew SNATS shares are held by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are held by institutional investors. 1.0% of Smith & Nephew SNATS shares are held by insiders. Comparatively, 1.5% of Bausch + Lomb shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Smith & Nephew SNATS has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market.

Smith & Nephew SNATS presently has a consensus target price of $30.93, indicating a potential upside of 3.65%. Bausch + Lomb has a consensus target price of $18.08, indicating a potential upside of 11.45%. Given Bausch + Lomb's higher possible upside, analysts clearly believe Bausch + Lomb is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.40
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Smith & Nephew SNATS has a net margin of 0.00% compared to Bausch + Lomb's net margin of -4.21%. Bausch + Lomb's return on equity of 3.60% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
Bausch + Lomb	-4.21%	3.60%	1.69%

Summary

Bausch + Lomb beats Smith & Nephew SNATS on 8 of the 15 factors compared between the two stocks.

How does Bausch + Lomb compare to Solventum?

Bausch + Lomb (NYSE:BLCO) and Solventum (NYSE:SOLV) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Bausch + Lomb presently has a consensus target price of $18.08, indicating a potential upside of 11.45%. Solventum has a consensus target price of $85.91, indicating a potential upside of 15.42%. Given Solventum's stronger consensus rating and higher probable upside, analysts clearly believe Solventum is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Solventum	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46

Solventum has a net margin of 17.33% compared to Bausch + Lomb's net margin of -4.21%. Solventum's return on equity of 23.51% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-4.21%	3.60%	1.69%
Solventum	17.33%	23.51%	7.63%

Bausch + Lomb has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market. Comparatively, Solventum has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market.

Solventum has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.13	-$360M	-$0.62	N/A
Solventum	$8.33B	1.55	$1.56B	$8.16	9.12

In the previous week, Solventum had 3 more articles in the media than Bausch + Lomb. MarketBeat recorded 6 mentions for Solventum and 3 mentions for Bausch + Lomb. Bausch + Lomb's average media sentiment score of 1.18 beat Solventum's score of 0.30 indicating that Bausch + Lomb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Solventum	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

11.1% of Bausch + Lomb shares are held by institutional investors. 1.5% of Bausch + Lomb shares are held by company insiders. Comparatively, 0.2% of Solventum shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Solventum beats Bausch + Lomb on 12 of the 15 factors compared between the two stocks.

How does Bausch + Lomb compare to Penumbra?

Bausch + Lomb (NYSE:BLCO) and Penumbra (NYSE:PEN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Bausch + Lomb presently has a consensus target price of $18.08, indicating a potential upside of 11.45%. Penumbra has a consensus target price of $361.33, indicating a potential upside of 12.05%. Given Penumbra's higher probable upside, analysts clearly believe Penumbra is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18

Penumbra has a net margin of 11.76% compared to Bausch + Lomb's net margin of -4.21%. Penumbra's return on equity of 10.87% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-4.21%	3.60%	1.69%
Penumbra	11.76%	10.87%	8.45%

Bausch + Lomb has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market. Comparatively, Penumbra has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

Penumbra has lower revenue, but higher earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.13	-$360M	-$0.62	N/A
Penumbra	$1.40B	9.04	$177.69M	$4.34	74.30

In the previous week, Penumbra had 5 more articles in the media than Bausch + Lomb. MarketBeat recorded 8 mentions for Penumbra and 3 mentions for Bausch + Lomb. Bausch + Lomb's average media sentiment score of 1.18 beat Penumbra's score of 0.03 indicating that Bausch + Lomb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Penumbra	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

11.1% of Bausch + Lomb shares are held by institutional investors. Comparatively, 88.9% of Penumbra shares are held by institutional investors. 1.5% of Bausch + Lomb shares are held by company insiders. Comparatively, 2.9% of Penumbra shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Penumbra beats Bausch + Lomb on 12 of the 16 factors compared between the two stocks.

How does Bausch + Lomb compare to Glaukos?

Bausch + Lomb (NYSE:BLCO) and Glaukos (NYSE:GKOS) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

11.1% of Bausch + Lomb shares are owned by institutional investors. Comparatively, 99.0% of Glaukos shares are owned by institutional investors. 1.5% of Bausch + Lomb shares are owned by company insiders. Comparatively, 5.8% of Glaukos shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Bausch + Lomb has a net margin of -4.21% compared to Glaukos' net margin of -34.34%. Bausch + Lomb's return on equity of 3.60% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-4.21%	3.60%	1.69%
Glaukos	-34.34%	-6.92%	-5.25%

Bausch + Lomb presently has a consensus target price of $18.08, indicating a potential upside of 11.45%. Glaukos has a consensus target price of $144.42, indicating a potential upside of 5.27%. Given Bausch + Lomb's higher possible upside, equities analysts plainly believe Bausch + Lomb is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Glaukos	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Bausch + Lomb has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market. Comparatively, Glaukos has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market.

Glaukos has lower revenue, but higher earnings than Bausch + Lomb. Glaukos is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.13	-$360M	-$0.62	N/A
Glaukos	$507.44M	15.88	-$187.69M	-$3.28	N/A

In the previous week, Glaukos had 1 more articles in the media than Bausch + Lomb. MarketBeat recorded 4 mentions for Glaukos and 3 mentions for Bausch + Lomb. Bausch + Lomb's average media sentiment score of 1.18 beat Glaukos' score of 0.85 indicating that Bausch + Lomb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Glaukos	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Glaukos beats Bausch + Lomb on 9 of the 17 factors compared between the two stocks.

Get Bausch + Lomb News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLCO vs. The Competition

Export

Metric	Bausch + Lomb	Medical Services Industry	Medical Sector	NYSE Exchange
Market Cap	$5.72B	$8.31B	$6.30B	$22.96B
Dividend Yield	N/A	2.92%	2.79%	4.07%
P/E Ratio	-26.17	22.95	21.00	28.29
Price / Sales	1.13	15.56	554.55	24.51
Price / Cash	9.61	83.95	42.94	25.11
Price / Book	0.90	5.62	9.75	4.73
Net Income	-$360M	$183.43M	$3.55B	$1.07B
7 Day Performance	1.95%	0.28%	-0.53%	-1.11%
1 Month Performance	-3.02%	5.23%	1.20%	1.36%
1 Year Performance	42.70%	4.94%	41.22%	24.41%

Bausch + Lomb Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLCO Bausch + Lomb	4.4145 of 5 stars	$16.23 +1.2%	$18.08 +11.5%	+36.8%	$5.72B	$5.10B	N/A	13,000
ZBH Zimmer Biomet	4.5394 of 5 stars	$82.24 -1.4%	$102.80 +25.0%	-15.1%	$15.93B	$8.23B	21.36	17,000	Positive News
SNN Smith & Nephew SNATS	2.5601 of 5 stars	$29.90 -0.5%	$34.75 +16.2%	+5.6%	$12.79B	$6.16B	N/A	16,988	Analyst Forecast
SOLV Solventum	3.2315 of 5 stars	$73.30 +2.3%	$85.91 +17.2%	+0.9%	$12.71B	$8.33B	8.98	20,000
PEN Penumbra	3.3802 of 5 stars	$322.15 -0.8%	$361.33 +12.2%	+9.1%	$12.67B	$1.45B	74.23	4,700	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BLCO) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bausch + Lomb (BLCO) Competitors

BLCO vs. ZBH, SNN, SOLV, PEN, and GKOS

How does Bausch + Lomb compare to Zimmer Biomet?

Summary

How does Bausch + Lomb compare to Smith & Nephew SNATS?

Summary

How does Bausch + Lomb compare to Solventum?

Summary

How does Bausch + Lomb compare to Penumbra?

Summary

How does Bausch + Lomb compare to Glaukos?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLCO vs. The Competition

Bausch + Lomb Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bausch + Lomb (BLCO) Competitors

BLCO vs. ZBH, SNN, SOLV, PEN, and GKOS

How does Bausch + Lomb compare to Zimmer Biomet?

Which has preferable valuation and earnings, BLCO or ZBH?

Does the media refer more to BLCO or ZBH?

Do insiders & institutionals have more ownership in BLCO or ZBH?

Which has more volatility and risk, BLCO or ZBH?

Do analysts rate BLCO or ZBH?

Is BLCO or ZBH more profitable?

Summary

How does Bausch + Lomb compare to Smith & Nephew SNATS?

Which has higher valuation & earnings, SNN or BLCO?

Does the media refer more to SNN or BLCO?

Do institutionals and insiders have more ownership in SNN or BLCO?

Which has more volatility & risk, SNN or BLCO?

Do analysts prefer SNN or BLCO?

Is SNN or BLCO more profitable?

Summary

How does Bausch + Lomb compare to Solventum?

Do analysts prefer BLCO or SOLV?

Is BLCO or SOLV more profitable?

Which has more risk & volatility, BLCO or SOLV?

Which has stronger valuation and earnings, BLCO or SOLV?

Does the media refer more to BLCO or SOLV?

Do insiders & institutionals have more ownership in BLCO or SOLV?

Summary

How does Bausch + Lomb compare to Penumbra?

Do analysts prefer BLCO or PEN?

Is BLCO or PEN more profitable?

Which has more risk & volatility, BLCO or PEN?

Which has stronger valuation and earnings, BLCO or PEN?

Does the media refer more to BLCO or PEN?

Do insiders & institutionals have more ownership in BLCO or PEN?

Summary

How does Bausch + Lomb compare to Glaukos?

Do institutionals & insiders have more ownership in BLCO or GKOS?

Is BLCO or GKOS more profitable?

Do analysts prefer BLCO or GKOS?

Which has more risk and volatility, BLCO or GKOS?

Which has higher valuation & earnings, BLCO or GKOS?

Does the media prefer BLCO or GKOS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLCO vs. The Competition

Bausch + Lomb Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools